Strategic steps for advanced molecular imaging with magnetic resonance-based diagnostic modalities.

With the rapidly-expanding sophistication in our understanding of cancer cell biology, molecular imaging offers a critical bridge to oncology. Molecular imaging through magnetic resonance spectroscopy (MRS) can provide information about many metabolites at the same time. Since MRS entails no ionizing radiation, repeated monitoring, including screening can be performed. However, MRS via the fast Fourier transform (FFT) has poor resolution and signal-to-noise ratio (SNR). Moreover, subjective and non-unique (ambiguous) fittings of FFT spectra cannot provide reliable quantification of clinical usefulness. In sharp contrast, objective and unique (unambiguous) signal processing by the fast Padé transform (FPT) can increase resolution and retrieve the true quantitative metabolic information. To illustrate, we apply the FPT to in vitro MRS data as encoded from malignant ovarian cyst fluid and perform detailed analysis. This problem area is particularly in need of timely diagnostics by more advanced modalities, such as high-resolution MRS, since conventional methods usually detect ovarian cancers at late stages with poor prognosis, whereas at an early stage the prognosis is excellent. The reliability and robustness of the FPT is assessed for time signals contaminated with varying noise levels. In the presence of higher background noise, all physical metabolites were unequivocally identified and their concentrations precisely extracted, using small fractions of the total signal length. Via the "signal-noise separation" concept alongside the "stability test", all non-physical information was binned, such that fully denoised spectra were generated. These results imply that a reformulation of data acquisition is needed, as guided by the FPT in MRS, since a small number of short transient time signals can provide high resolution and good SNR. This would enhance the diagnostic accuracy of MRS and shorten examination times, thereby improving efficiency and cost-effectiveness of this high throughput cancer diagnostic modality. Such advantages could be particularly important for more effective ovarian cancer detection, as well as more broadly for improved diagnostics and treatment within oncology.

[1]  A. Heerschap,et al.  1H‐magnetic resonance spectroscopy , 1998, Cancer.

[2]  S. Bhoola,et al.  Diagnosis and Management of Epithelial Ovarian Cancer , 2006, Obstetrics and gynecology.

[3]  Mauricio Castillo,et al.  Clinical role of proton magnetic resonance spectroscopy in oncology: brain, breast, and prostate cancer. , 2006, The Lancet. Oncology.

[4]  Guoying Liu,et al.  Expanding the use of magnetic resonance in the assessment of tumor response to therapy: workshop report. , 2005, Cancer research.

[5]  D. Belkić Exact quantification of time signals in Padé-based magnetic resonance spectroscopy , 2006, Physics in medicine and biology.

[6]  F. Podo,et al.  In Vivo Detection of Choline in Ovarian Tumors Using 3D Magnetic Resonance Spectroscopy , 2011, Investigative radiology.

[7]  Ie-Ming Shih,et al.  Early detection and treatment of ovarian cancer: shifting from early stage to minimal volume of disease based on a new model of carcinogenesis. , 2008, American journal of obstetrics and gynecology.

[8]  Klemens Scheidhauer,et al.  Use of positron emission tomography for response assessment of lymphoma: consensus of the Imaging Subcommittee of International Harmonization Project in Lymphoma. , 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[9]  S. Provencher Estimation of metabolite concentrations from localized in vivo proton NMR spectra , 1993, Magnetic resonance in medicine.

[10]  Thomas F Hany,et al.  Integrated PET/CT: current applications and future directions. , 2006, Radiology.

[11]  N. Jagannathan,et al.  Prebiopsy magnetic resonance spectroscopy and imaging in the diagnosis of prostate cancer , 2012, International journal of urology : official journal of the Japanese Urological Association.

[12]  Mauricio Castillo,et al.  Clinical Applications of Proton MR Spectroscopy in Oncology , 2002, Technology in cancer research & treatment.

[13]  A. R.,et al.  Review of literature , 1951, American Potato Journal.

[14]  D P Auer,et al.  On the reliability of quantitative clinical magnetic resonance spectroscopy of the human brain , 1995, NMR in biomedicine.

[15]  R. Knapp,et al.  Long-term follow-up of the Stockholm screening study on ovarian cancer. , 2000, Gynecologic oncology.

[16]  Catherine A. Ojo Analysis & automatic classification of nuclear magnetic resonance signals , 2010 .

[17]  U. Engelke,et al.  High‐resolution proton nuclear magnetic resonance spectroscopy of ovarian cyst fluid , 2000, NMR in biomedicine.

[18]  E. Melhem,et al.  Clinical Application of MR Spectroscopy and Imaging of Brain Tumor. , 2010, Magnetic resonance in medical sciences : MRMS : an official journal of Japan Society of Magnetic Resonance in Medicine.

[19]  A. Rockall,et al.  Imaging strategy for early ovarian cancer: characterization of adnexal masses with conventional and advanced imaging techniques. , 2012, Radiographics : a review publication of the Radiological Society of North America, Inc.

[20]  M. Garwood,et al.  Simultaneous in vivo spectral editing and water suppression , 1998, NMR in biomedicine.

[21]  O. Bouché,et al.  Imaging techniques to evaluate the response to treatment in oncology: current standards and perspectives. , 2009, Critical reviews in oncology/hematology.

[22]  K. Johnson An Update. , 1984, Journal of food protection.

[23]  B. Sitter,et al.  Metabolite composition in breast tumors examined by proton nuclear magnetic resonance spectroscopy. , 1999, Anticancer research.

[24]  P. Bottomley,et al.  The trouble with spectroscopy papers , 1992, Journal of magnetic resonance imaging : JMRI.

[25]  Dzevad Belkic,et al.  Spectroscopic imaging through magnetic resonance for brain tumour diagnostics: Recent achievements, dilemmas and potential solutions via advances in signal processing , 2004, J. Comput. Methods Sci. Eng..

[26]  D. Belkić,et al.  Exact quantification of time signals from magnetic resonance spectroscopy by the fast Padé transform with applications to breast cancer diagnostics , 2009 .

[27]  Jeffrey D Blume,et al.  Reasons women at elevated risk of breast cancer refuse breast MR imaging screening: ACRIN 6666. , 2010, Radiology.

[28]  P J Drew,et al.  Current applications and future direction of MR mammography , 2003, British Journal of Cancer.

[29]  Karen Belkić,et al.  Signal Processing in Magnetic Resonance Spectroscopy with Biomedical Applications , 2010 .

[30]  D. Belkić,et al.  Magnetic resonance spectroscopy with high-resolution and exact quantification in the presence of noise for improving ovarian cancer detection , 2012, Journal of Mathematical Chemistry.

[31]  P. Carroll,et al.  Quantitative analysis of prostate metabolites using 1H HR‐MAS spectroscopy , 2006, Magnetic resonance in medicine.

[32]  H. Hricak,et al.  MR imaging and MR spectroscopic imaging in the pre-treatment evaluation of prostate cancer. , 2005, The British journal of radiology.

[33]  I. Gribbestad,et al.  MRS and MRSI guidance in molecular medicine: targeting and monitoring of choline and glucose metabolism in cancer , 2011, NMR in biomedicine.

[34]  L. Gluch MAGNETIC RESONANCE IN SURGICAL ONCOLOGY: II – LITERATURE REVIEW , 2005, ANZ journal of surgery.

[35]  D. Belkić Exponential convergence rate (the spectral convergence) of the fast Padé transform for exact quantification in magnetic resonance spectroscopy , 2006, Physics in medicine and biology.

[36]  C. Mountford,et al.  Proton MRS can determine the pathology of human cancers with a high level of accuracy. , 2004, Chemical reviews.

[37]  Z. Bhujwalla,et al.  Molecular Causes of the Aberrant Choline Phospholipid Metabolism in Breast Cancer , 2004, Cancer Research.

[38]  R. Kauppinen,et al.  Using magnetic resonance imaging and spectroscopy in cancer diagnostics and monitoring , 2011, Cancer biology & therapy.

[39]  D. Belkić Quantum-Mechanical Signal Processing and Spectral Analysis , 2004 .

[40]  R. Lenkinski,et al.  Clinical utility of proton magnetic resonance spectroscopy in characterizing breast lesions. , 2002, Journal of the National Cancer Institute.

[41]  Hedvig Hricak,et al.  Molecular imaging for personalized cancer care , 2012, Molecular oncology.